Personalized immune cells tested against Tough-to-Treat brain melanoma
NCT ID NCT05640193
Summary
This early-stage study is testing a personalized cell therapy called lifileucel for patients whose melanoma has spread to the brain and is no longer responding to standard immunotherapy. Doctors will collect a patient's own tumor-fighting immune cells, grow them in a lab, and infuse them back into the patient to try to control the cancer. The main goal is to see if this complex treatment process is feasible and safe for these patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.